Modality
Small Molecule
MOA
FGFRi
Target
BTK
Pathway
DDR
Thymoma
Development Pipeline
Preclinical
~Oct 2016
→ ~Jan 2018
Phase 1
~Apr 2018
→ ~Jul 2019
Phase 2
Oct 2019
→ Sep 2030
Phase 2Current
NCT05730952
765 pts·Thymoma
2019-10→2030-09·Active
765 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-09-154.5y awayPh2 Data· Thymoma
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2
Active
Catalysts
Ph2 Data
2030-09-15 · 4.5y away
Thymoma
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05730952 | Phase 2 | Thymoma | Active | 765 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| 369-8021 | Hansoh Pharma | Approved | BTK | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 | |
| Pemitinib | Xenon Pharma | Preclinical | BTK |